Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010

O Wichmann; P Stöcker; G Poggensee; D Altmann; D Walter; W Hellenbrand; G Krause; T Eckmanns

doi:10.2807/ese.15.18.19561-en

Rapid communications Open Access

Like 0

Download

Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010
O Wichmann¹ , P Stöcker¹ , G Poggensee¹ , D Altmann¹ , D Walter¹ , W Hellenbrand¹ , G Krause¹ , T Eckmanns¹
View Affiliations Hide Affiliations

Affiliations: ¹ Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

Correspondence:
O Wichmann
WichmannO rki.de
View Citation Hide Citation

Citation style for this article: Wichmann O, Stöcker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 2010;15(18):pii=19561. https://doi.org/10.2807/ese.15.18.19561-en Received: 05 May 2010

Previous Article
Table of Contents
Next Article

Abstract

During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).